drugset / Trial / NCT07076095
A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer
Phase 2
Not yet recruiting
200 enrolled
SUNHO（China）BioPharmaceutical CO., Ltd.
Zhengzhou University · collab
NaParallel-groupOpen-labelTreatment
Summary
This study was designed to compare the efficacy and safety of IBB0979 in combination with topotecan versus topotecan in subjects with relapsed small cell lung cancer (SCLC).
Timeline
- Start
- 2025-08-01
- Primary completion
- 2028-08-01
- Completion
- 2031-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IBB0979 | Unknown | — | Intravenous |
| Subject | Topotecan | Small molecule | — | Intravenous |